AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aytu BioPharma insiders have made significant purchases of company stock in the last year, with CEO Joshua Disbrow buying $100k worth of shares at $1.50 per share. However, insider ownership is only 5.4% of the company, which is considered relatively low. Despite this, insider buying is generally seen as a positive sign for shareholders.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet